Clinical trial
Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to…
NCT00197028 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00197028 |
|---|---|
| Title | Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region |
| Official title | A Phase I/IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02D, a Candidate Malaria Vaccine in Infants Living in a Malaria-endemic Region |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malaria |
| Intervention type | Biological |
| Interventions | RTS, S/AS02D, TETRActHib™, Engerix-B® |
| Enrollment | 214 |
| Start date | Aug 23, 2005 |
| Primary completion | Dec 27, 2007 |
| Completion | Dec 27, 2007 |
| First posted | Sep 20, 2005 |
| Last update posted | Aug 20, 2018 |
| Countries | Mozambique |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: